Clinical Study Shows Improved Absorption of Desmopressin with Novel Formulation

Overview

Journal Pharm Res

Specialties Pharmacology
Pharmacy

Date 2009 Mar 20

PMID 19296208

Citations 10

Authors

Nelly Fransen

Susanne Bredenberg

Erik Bjork

Affiliations

Soon will be listed here.

Abstract

Purpose: To create improved pharmaceutical formulations for nasal and sublingual administration of desmopressin and investigate their pharmacokinetic profiles in comparison with a commercial nasal liquid spray and finally to evaluate the volunteers' opinions on the different dosage forms.

Methods: Both formulations were based on the characteristics of interactive mixtures. The nasal powder spray was produced by a rotary evaporator technique with sodium starch glycolate as carrier material and the sublingual tablet by direct compression after dry mixing with mannitol as carrier. The clinical study was an open-label, randomised cross-over pharmacokinetic study in healthy volunteers.

Results: The nasal powder formulation gave a threefold increase in the absorption, unaltered time to maximum plasma concentration and a tendency to lower variability in the amount absorbed compared with the liquid spray. The powder was reported to be more irritating than the liquid but was still well accepted by the volunteers. The tablet did not improve the uptake of desmopressin, likely because of a poor disintegration sublingually.

Conclusions: The nasal powder formulation is a promising new dosage form for the delivery of desmopressin and other compounds. The sublingual tablet has a beneficial means of production and may be further developed by decreasing its disintegration time.

Citing Articles

The Upper Nasal Space: Option for Systemic Drug Delivery, Mucosal Vaccines and "Nose-to-Brain".

Shrewsbury S Pharmaceutics. 2023; 15(6).

PMID: 37376168 PMC: 10303426. DOI: 10.3390/pharmaceutics15061720.

Nose-to-Brain Delivery of Therapeutic Peptides as Nasal Aerosols.

Alabsi W, Eedara B, Encinas-Basurto D, Polt R, Mansour H Pharmaceutics. 2022; 14(9).

PMID: 36145618 PMC: 9502087. DOI: 10.3390/pharmaceutics14091870.

Nasal Powder Formulations: In-Vitro Characterisation of the Impact of Powders on Nasal Residence Time and Sensory Effects.

Trenkel M, Scherliess R Pharmaceutics. 2021; 13(3).

PMID: 33805779 PMC: 8001606. DOI: 10.3390/pharmaceutics13030385.

Just how prevalent are peptide therapeutic products? A critical review.

Zhang Y, Zhang H, Ghosh D, Williams 3rd R Int J Pharm. 2020; 587:119491.

PMID: 32622810 PMC: 10655677. DOI: 10.1016/j.ijpharm.2020.119491.

Population Pharmacokinetic Modeling of a Desmopressin Oral Lyophilisate in Growing Piglets as a Model for the Pediatric Population.

Gasthuys E, Vermeulen A, Croubels S, Millecam J, Schauvliege S, van Bergen T Front Pharmacol. 2018; 9:41.

PMID: 29445339 PMC: 5797931. DOI: 10.3389/fphar.2018.00041.

References

Fjellestad-Paulsen A, Hoglund P, Rambaud J . Bioavailability of 1-deamino-8-D-arginine vasopressin with an enzyme inhibitor (aprotinin) from the small intestine in healthy volunteers. Eur J Clin Pharmacol. 1996; 50(6):491-5. DOI: 10.1007/s002280050146. View

Eller N, Kollenz C, Hitzenberger G . A comparative study of pharmacodynamics and bioavailability of 2 different desmopressin nasal sprays. Int J Clin Pharmacol Ther. 1998; 36(3):139-45. View

Harris D, Robinson J . Drug delivery via the mucous membranes of the oral cavity. J Pharm Sci. 1992; 81(1):1-10. DOI: 10.1002/jps.2600810102. View

Ryan R, Elkind A, Baker C, MULLICAN W, DeBussey S, Asgharnejad M . Sumatriptan nasal spray for the acute treatment of migraine. Results of two clinical studies. Neurology. 1997; 49(5):1225-30. DOI: 10.1212/wnl.49.5.1225. View

Harris A, Ohlin M, Svensson E, Lethagen S, Nilsson I . Effect of viscosity on the pharmacokinetics and biological response to intranasal desmopressin. J Pharm Sci. 1989; 78(6):470-1. DOI: 10.1002/jps.2600780610. View

Kaehler S, Steiner I, Sauermann R, Scheidl H, Mueller M, Joukhadar C . A bioequivalence study of two oral desmopressin tablet formulations. Pharmacology. 2006; 77(1):46-52. DOI: 10.1159/000092625. View

Teshima D, Yamauchi A, Makino K, Kataoka Y, Arita Y, Nawata H . Nasal glucagon delivery using microcrystalline cellulose in healthy volunteers. Int J Pharm. 2002; 233(1-2):61-6. DOI: 10.1016/s0378-5173(01)00930-9. View

Luessen H, de Leeuw B, Langemeyer M, de Boer A, Verhoef J, Junginger H . Mucoadhesive polymers in peroral peptide drug delivery. VI. Carbomer and chitosan improve the intestinal absorption of the peptide drug buserelin in vivo. Pharm Res. 1996; 13(11):1668-72. DOI: 10.1023/a:1016488623022. View

Bjork E, Isaksson U, EDMAN P, Artursson P . Starch microspheres induce pulsatile delivery of drugs and peptides across the epithelial barrier by reversible separation of the tight junctions. J Drug Target. 1995; 2(6):501-7. DOI: 10.3109/10611869509015920. View

10.

Soane R, Frier M, Perkins A, Jones N, Davis S, Illum L . Evaluation of the clearance characteristics of bioadhesive systems in humans. Int J Pharm. 1999; 178(1):55-65. DOI: 10.1016/s0378-5173(98)00367-6. View

11.

Harris A, Ohlin M, Lethagen S, Nilsson I . Effects of concentration and volume on nasal bioavailability and biological response to desmopressin. J Pharm Sci. 1988; 77(4):337-9. DOI: 10.1002/jps.2600770412. View

12.

Bredenberg S, Duberg M, Lennernas B, Lennernas H, Pettersson A, Westerberg M . In vitro and in vivo evaluation of a new sublingual tablet system for rapid oromucosal absorption using fentanyl citrate as the active substance. Eur J Pharm Sci. 2003; 20(3):327-34. DOI: 10.1016/j.ejps.2003.07.002. View

13.

Harris A, Svensson E, Wagner Z, Lethagen S, Nilsson I . Effect of viscosity on particle size, deposition, and clearance of nasal delivery systems containing desmopressin. J Pharm Sci. 1988; 77(5):405-8. DOI: 10.1002/jps.2600770510. View

14.

Callens C, Remon J . Evaluation of starch-maltodextrin-Carbopol 974 P mixtures for the nasal delivery of insulin in rabbits. J Control Release. 2000; 66(2-3):215-20. DOI: 10.1016/s0168-3659(99)00271-0. View

15.

Osterberg O, Savic R, Karlsson M, Simonsson U, Norgaard J, Walle J . Pharmacokinetics of desmopressin administrated as an oral lyophilisate dosage form in children with primary nocturnal enuresis and healthy adults. J Clin Pharmacol. 2006; 46(10):1204-11. DOI: 10.1177/0091270006291838. View

16.

Yamamoto A, Iseki T, Okada N, Fujita T, Muranishi S . Absorption of water-soluble compounds with different molecular weights and. J Control Release. 2001; 76(3):363-74. DOI: 10.1016/s0168-3659(01)00454-0. View

17.

Callens C, Adriaens E, Dierckens K, Remon J . Toxicological evaluation of a bioadhesive nasal powder containing a starch and Carbopol 974 P on rabbit nasal mucosa and slug mucosa. J Control Release. 2001; 76(1-2):81-91. DOI: 10.1016/s0168-3659(01)00419-9. View

18.

Joukhadar C, Schenk B, Kaehler S, Kollenz C, Bauer P, Muller M . A replicate study design for testing bioequivalence: a case study on two desmopressin nasal spray preparations. Eur J Clin Pharmacol. 2003; 59(8-9):631-6. DOI: 10.1007/s00228-003-0682-3. View

19.

Fransen N, Bjork E, Nystrom C . Development and characterisation of interactive mixtures with a fine-particulate mucoadhesive carrier for nasal drug delivery. Eur J Pharm Biopharm. 2007; 67(2):370-6. DOI: 10.1016/j.ejpb.2007.03.006. View

20.

Li L, Mathias N, Heran C, Moench P, Wall D, Smith R . Carbopol-mediated paracellular transport enhancement in Calu-3 cell layers. J Pharm Sci. 2005; 95(2):326-35. DOI: 10.1002/jps.20541. View